About this trial
Last updated 14 years ago
Study ID
Cypro-24
Status
Unknown status
Type
Interventional
Phase
Phase 4
Placebo
No
Accepting
2 to 4 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 13 years ago
What is this trial about?
Cyproheptadine is currently clinically used as an appetite stimulant for children with
failure to thrive without underlying organic disease. Otherwise, no randomised control trial
demonstrates the efficacy of Cyproheptadine on those patients. This is precisely what the
investigators intend to demonstrate on this randomised placebo control cross-over trial. Our
hypothesis is that Cyproheptadine is more efficient than placebo to improve weight gain and
feeding behaviour on 2 to 4 years old children with failure to thrive.
What are the participation requirements?
Inclusion Criteria
- 2 to 4 years of age
- failure to thrive
Exclusion Criteria
- Medication affecting appetite
- Medication interacting with Cyproheptadine
- Prematurity under 36 weeks of gestation
- Neurologic impairment
- underlying organic disease